What Researchers Did
Researchers conducted a retrospective cohort study of 39 patients with necrotizing soft tissue infections (NSTIs) secondary to gastrointestinal fistulas, analyzing clinical characteristics, microbiology, and outcomes.
What They Found
In-hospital mortality was 38.5%. Klebsiella pneumoniae was the most common organism (41%). Only 2 of 39 patients received HBOT. Non-survivors had higher APACHE II scores, lower source control rates within 48 hours, and lower platelet counts than survivors.
What This Means for Canadian Patients
GI fistula-related necrotizing infections carry very high mortality. This study highlights that source control speed is the key survival factor. For Canadian surgical teams, HBOT appears underutilized in this context -- though the tiny number treated makes conclusions about its role impossible.
Canadian Relevance
No direct Canadian connection identified.
Study Limitations
Only 2 patients received HBOT in this study, making it impossible to draw any conclusions about HBOT efficacy; the primary findings concern surgical management, not hyperbaric therapy.